论文部分内容阅读
以萘心安(心得安)为代表的肾上腺素能β受体阻滞剂是六十年代发展起来的一类重要药物,也是过去二十年来心血管疾病药物治疗上最重要的进展之一。自从1958年报道第一个具有β受体阻滞作用的双氯异丙肾上腺素起,二十年间这类药物取得了长足的进展,如今已上临床的品种至少在30种以上。它们不仅适用于治疗心律失常、心绞痛和高血压等心血管疾病,同时对某些其它疾病如偏头痛、震颤、焦虑及精神分裂症等也有疗效。特别是最近几年,大量研究证明β受体阻滞剂对高血压病具有比较理想的效果,长期使用能显著降低高血压病和冠心病患者的心肌梗塞发生率和猝死率,因此这类药物具有极大的临床意义。本文拟将β受体阻滞剂及其分类和评价等问题作一简要介绍,以利促进这类药物在我国人民卫生保健事业中发挥更大的作用。
Adrenergic beta blockers, represented by propranolol, are one of the most important drugs developed in the 1960s and one of the most important advances in the treatment of cardiovascular diseases over the past two decades. Since 1958 the first beta-blocker epinephrine has been reported, considerable progress has been made in these two decades and there are now at least 30 clinically proven varieties. They are not only suitable for the treatment of cardiovascular diseases such as arrhythmia, angina and hypertension, but also for some other diseases such as migraine, tremor, anxiety and schizophrenia. In recent years, in particular, a large number of studies have shown that β blockers have an ideal effect on hypertension, long-term use can significantly reduce the incidence of myocardial infarction and sudden death in patients with hypertension and coronary heart disease, and therefore these drugs Has great clinical significance. This article intends to beta blockers and classification and evaluation of such issues as a brief introduction to facilitate the promotion of such drugs in our people’s health care to play a greater role.